Apr 10, 2021
Current clinical characteristics and demographics are not sufficient to capture aggressive disease in clinical trials of newly diagnosed DLBCL. Novel tools, such as measurement of tumor burden via ctDNA, are needed.
TRANSCRIPT
This JCO Podcast provides observations and commentary on the JCO article “Short...